BRAF and melanoma: On the contrary, combination therapies with the BRAF/MEK inhibitors (dabrafenib/trametinib) have shown a longer duration of survival than placebo in stage III melanoma (5‐year disease‐free survival (DFS), 52% versus 36%; hazard ratio (HR), 0.51).7